Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lipovirtide in HIV-infected Patients Without Prior Antiviral Therapy
NCT04592315Phase 1Completed
- Sponsor
- Shanxi Kangbao Biological Products
- Start
- Jan 2021
- Primary completion
- May 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1 trial of lipovirtide in human immunodeficiency virus infection (HIV) (6 arms), sponsored by Shanxi Kangbao Biological Products. Primary endpoint: Treatment-Related Adverse Events at 15 days. Started Jan 2021; status: completed.
02
Drugs
lipovirtide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04592315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592315.